SIGN UP
LOG IN
News
Alphamab Oncology
--
--
0.00%
Weekly Report: what happened at Alphamab Oncology last week (0707-0711)?
Weekly Report · 4d ago
Weekly Report: what happened at Alphamab Oncology last week (0630-0704)?
Weekly Report · 07/06 22:04
Weekly Report: what happened at Alphamab Oncology last week (0623-0627)?
Weekly Report · 06/29 22:05
Alphamab Oncology (HKG:9966) Could Easily Take On More Debt
Simply Wall St · 06/26 23:15
Weekly Report: what happened at Alphamab Oncology last week (0616-0620)?
Weekly Report · 06/22 22:04
Weekly Report: what happened at Alphamab Oncology last week (0609-0613)?
Weekly Report · 06/15 22:05
Weekly Report: what happened at Alphamab Oncology last week (0602-0606)?
Weekly Report · 06/08 22:05
Weekly Report: what happened at Alphamab Oncology last week (0526-0530)?
Weekly Report · 06/01 22:05
Alphamab Oncology's (HKG:9966) 38% Price Boost Is Out Of Tune With Revenues
Simply Wall St · 05/31 01:19
Weekly Report: what happened at Alphamab Oncology last week (0519-0523)?
Weekly Report · 05/25 22:05
Weekly Report: what happened at Alphamab Oncology last week (0512-0516)?
Weekly Report · 05/18 22:05
BUZZ-Alphamab Oncology leads slide in HK pharma stocks on Trump's plan to trim medicine prices
Reuters · 05/12 07:42
Weekly Report: what happened at Alphamab Oncology last week (0505-0509)?
Weekly Report · 05/11 22:05
Alphamab Oncology Full Year 2024 Earnings: Beats Expectations
Simply Wall St · 05/05 00:04
Weekly Report: what happened at Alphamab Oncology last week (0428-0502)?
Weekly Report · 05/04 22:05
Weekly Report: what happened at Alphamab Oncology last week (0421-0425)?
Weekly Report · 04/27 22:05
Weekly Report: what happened at Alphamab Oncology last week (0414-0418)?
Weekly Report · 04/20 22:05
Revenues Not Telling The Story For Alphamab Oncology (HKG:9966) After Shares Rise 26%
Simply Wall St · 04/15 23:02
Weekly Report: what happened at Alphamab Oncology last week (0407-0411)?
Weekly Report · 04/13 22:05
Weekly Report: what happened at Alphamab Oncology last week (0331-0404)?
Weekly Report · 04/06 22:05
About Alphamab Oncology
Alphamab Oncology is an investment holding company principally engaged in research and development, manufacturing and commercialisation of biologics of oncology. The Company’s highly differentiated in-house pipeline consists of monoclonal antibodies, bispecific antibodies, and ADCs in staggered development status in oncology. The Company’s drug candidates include KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), and others, used for indications such as 1L pancreatic cancer, 1L breast cancer, advanced solid tumors, and HER2-expressing solid tumors.
MoreRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.